Key Drivers
- Margin Strength
- Balance-Sheet Risk
- Premium Pricing
AIAI Summary
Amgen is increasingly a broad-based growth story rather than just a defensive pharma name, but after the sharp rerating it is now a prove-it stock: investors need to see multi-quarter durability in the new growth drivers while leverage, legal exposure, and biosimilar pressure remain contained, because the premium valuation already assumes continued execution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Balance-Sheet Risk
- •Premium Pricing
AMGN posted strong margins and free cash flow with improving liquidity, but high leverage, large intangibles, and a rich multiple suggest the stock is priced for perfection.
Price Behavior
Key Price Behavior Insights:
- •Strong Uptrend
- •Near Resistance
- •Pullback Risk
AMGN has been in a strong uptrend over the last month, but after a sharp move into the $418 resistance area, it looks stretched and may need to consolidate before extending higher.
Sharp run from the mid-$360s to above $415 in a short period suggests short-term stretch and consolidation risk
Sentiment & News
Key News Insights:
- •Q2 Beat
- •Raised Outlook
- •Mixed Ownership
Amgen delivered a strong Q2 beat with revenue topping $10B, raised full-year guidance, and saw shares jump despite biosimilar and legacy-drug pressures.
The news is net positive for Amgen, signaling improving operating momentum and near-term upside, though competitive pressures and heavy reinvestment remain watchpoints
Similar Companies in Healthcare
Other companies in the same sector with AI ratings